Day One Biopharma up after FDA accepts marketing application of brain tumor therapy

Day One Biopharmaceuticals

30/10/2023 14:38

** Day One Biopharmaceuticals's shares  DAWN.O  rise 13% to
$11.5 - biggest pct. gain in five month 
    ** Drug developer said U.S. FDA accepted marketing
application for its monotherapy to treat children with a type of
brain tumor
    ** FDA has granted priority review and assigned a PDUFA date
of April 30, 2024
     ** The FDA is not currently planning to hold an advisory
committee meeting to discuss the application - DAWN
    ** Including session gains, stock had fallen ~47% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))